The independent, National Institutes of Health (NIH)-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, has informed Moderna Inc. that the trial for its COVID-19 vaccine ...
CAMBRIDGE, MA / ACCESSWIRE / December 15, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced the publication of positive Phase 3 clinical study results evaluating mRNA-1345, its vaccine candidate for ...
Hosted on MSN
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna ...
Moderna on Tuesday released preliminary data indicating its vaccine is likely to hold up against several variants of concern, including the Delta variant, which is predicted to become the dominant ...
CHICAGO, Sept 17 (Reuters) - If Moderna Inc's (MRNA.O), opens new tab COVID-19 vaccine proves to be at least 70% effective, the company plans to seek emergency authorization for its use in high-risk ...
CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...
Nov 11 (Reuters) - Moderna Inc (MRNA.O), opens new tab said on Wednesday it has enough data for a first interim analysis of the late-stage trial of its experimental COVID-19 vaccine, which should help ...
Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc GSK in a phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback